We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Magellan Healths Growth Measures Aid Investors' Confidence
Read MoreHide Full Article
Magellan Health, Inc.’s strategic initiatives to rake in growth seems to be slowly taking off. Though the company has sustained declining earnings and revenues for the first nine months of 2019, investors’ have been cognizant of the green shoots appearing in its Pharmacy Management business and greater clarity for its overall business performance.
Increased visibility for business growth in the second half of 2019 have supported the stock price gain of 7.8% compared with the industry’s decline of 5.4%. In 2018, the stock slid 41% due to its disappointing performance.
During June 2018, sources reported that Magellan Health was mulling its possible sale to private-equity firm Centerbridge Partners, after it came under pressure, due to its prolonged underperformance, from activist hedge fund Starboard Value, which owned nearly 10% stake in the company.
The second-quarter earnings provide a clearer visibility into second-half earnings performance. Though the company anticipates year-over-year decline in top line for 2019, it expects new business wins and lower costs to support overall results.
Magellan Health expects earnings growth in the Pharmacy Management segment, which contributed nearly 40% of total revenues in 2018. This should be driven on the back of improvement in cost of goods sold, addition of a new business in 2019, and a normal seasonality in the fourth quarter.
Also, Healthcare segment, which made up nearly 60% of the company’s revenues in 2018, should see higher earnings from the normalization of utilization and finalization of New York reimbursement rates.
The sale of Magellan Health has become deadlocked. Thus, it is focusing on business growth.
Magellan Health carries a Zacks Rank #3 (Hold). Some better-ranked players in the same space are Molina Healthcare, (MOH - Free Report) , UnitedHealthcare Group, Inc. (UNH - Free Report) and Cigna Corp. (CI - Free Report) . Each of these stocks carries a zacks rank #2 (Buy).
Cigna has surpassed earnings estimates in three of the four reported quarters by 7.02%. UnitedHealth and Molina Health have surpassed the same in each of the four reported quarters by 3.37% and 66.93%, respectively.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Magellan Healths Growth Measures Aid Investors' Confidence
Magellan Health, Inc.’s strategic initiatives to rake in growth seems to be slowly taking off. Though the company has sustained declining earnings and revenues for the first nine months of 2019, investors’ have been cognizant of the green shoots appearing in its Pharmacy Management business and greater clarity for its overall business performance.
Increased visibility for business growth in the second half of 2019 have supported the stock price gain of 7.8% compared with the industry’s decline of 5.4%. In 2018, the stock slid 41% due to its disappointing performance.
During June 2018, sources reported that Magellan Health was mulling its possible sale to private-equity firm Centerbridge Partners, after it came under pressure, due to its prolonged underperformance, from activist hedge fund Starboard Value, which owned nearly 10% stake in the company.
The second-quarter earnings provide a clearer visibility into second-half earnings performance. Though the company anticipates year-over-year decline in top line for 2019, it expects new business wins and lower costs to support overall results.
Magellan Health expects earnings growth in the Pharmacy Management segment, which contributed nearly 40% of total revenues in 2018. This should be driven on the back of improvement in cost of goods sold, addition of a new business in 2019, and a normal seasonality in the fourth quarter.
Also, Healthcare segment, which made up nearly 60% of the company’s revenues in 2018, should see higher earnings from the normalization of utilization and finalization of New York reimbursement rates.
The sale of Magellan Health has become deadlocked. Thus, it is focusing on business growth.
Magellan Health carries a Zacks Rank #3 (Hold). Some better-ranked players in the same space are Molina Healthcare, (MOH - Free Report) , UnitedHealthcare Group, Inc. (UNH - Free Report) and Cigna Corp. (CI - Free Report) . Each of these stocks carries a zacks rank #2 (Buy).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cigna has surpassed earnings estimates in three of the four reported quarters by 7.02%. UnitedHealth and Molina Health have surpassed the same in each of the four reported quarters by 3.37% and 66.93%, respectively.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>